Abstract
Sequential endoluminal gemcitabine and docetaxel versus bacillus Calmette–Guérin for the treatment of high-grade upper tract urothelial carcinoma
Journal of clinical oncology, Vol.42(4_suppl), pp.613-613
02/01/2024
DOI: 10.1200/JCO.2024.42.4_suppl.613
Abstract
613 Background: BCG is currently the only endoluminal treatment option for high-grade (HG) upper tract urothelial carcinoma (UTUC). Gemcitabine/Docetaxel (Gem/Doce) has shown promising efficacy as a treatment for HG UTUC, though a comparison to BCG is lacking. We report the outcomes of patients treated with endoluminal Gem/Doce versus BCG for non-invasive HG UTUC. Methods: A retrospective review of patients treated with Gem/Doce versus BCG for clinically non-invasive HG UTUC was performed. Treatment was instilled via nephrostomy or retrograde ureteral catheter. Induction instillations were performed weekly for 6 weeks. If disease free, maintenance therapy for Gem/Doce was monthly for 6 months and a single 3 week mini-cycle for BCG. Recurrence was defined as biopsy-proven disease or HG cytology. Progression was defined as development of muscle invasion, metastases, or death due to cancer. Results: The final cohort included 59 patients with 71 treated upper tract units; 36 received BCG and 35 received Gem/Doce. Median follow-up was 62 months in the BCG group and 29 months in the Gem/Doce group. Indication for treatment included a positive HG cytology in 78% and 89% of the BCG and Gem/Doce groups, respectively; the remaining patients in each group presented with pathologically-confirmed HG disease. The 2-year estimates for recurrence-free and nephroureterectomy-free survival were 57% and 87% for the BCG group and 56% and 100% for the Gem/Doce group, respectively (Table). Upon multivariable analysis, treatment with Gem/Doce was not associated with an increased risk of recurrence versus BCG (HR 0.78, 95%CI 0.33-1.85; p=0.57). In total, 19% of patients receiving BCG and 15% of patients receiving Gem/Doce experienced a grade 3+ adverse event. The development of any symptoms was not statistically different between treatment groups (p=0.28). There were two deaths recorded during the study period, one in each treatment group. Conclusions: Endoluminal Gem/Doce and BCG have similar oncological outcomes and major AE rates in the treatment of HG UTUC. Further prospective evaluation is warranted. [Table: see text]
Details
- Title: Subtitle
- Sequential endoluminal gemcitabine and docetaxel versus bacillus Calmette–Guérin for the treatment of high-grade upper tract urothelial carcinoma
- Creators
- Ian M. McElree - University of IowaSarah L. Mott - University of IowaVignesh T. Packiam - University of IowaMichael A. O'Donnell - University of IowaRyan L. Steinberg - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.42(4_suppl), pp.613-613
- DOI
- 10.1200/JCO.2024.42.4_suppl.613
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Grant note
- name: John & Carol Walter Family Foundation
- Language
- English
- Date published
- 02/01/2024
- Academic Unit
- Urology
- Record Identifier
- 9984554856002771
Metrics
1 Record Views